Sarepta touts clean data for commercial grade Duchenne gene therapy, clearing key hurdle to PhIII
After a trial flop and an unexpected detour, Sarepta says its gene therapy for Duchenne muscular dystrophy looks ready to get back on the Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
